Warren Center For Neuroscience Drug Discovery
-
Carrie Jones wins Wellcome Trust Discovery Award to combat opioid misuse and addiction
Great Britain’s Wellcome Trust has recognized Vanderbilt’s Carrie K. Jones and the University of Glasgow’s Andrew Tobin with their prestigious Discovery Award. The pair will study how blocking the M5 muscarinic receptor in the brain counteracts opioids’ addictive properties, which could lead to new treatments for preventing or addressing opioid addiction. Read MoreFeb. 10, 2025
-
Vanderbilt basic science alum Q&A: Ashley Brady
Ashley Brady, PhD’03, assistant dean of biomedical career engagement and strategic partnerships in the BRET Office of Career Development ASPIRE Program and associate professor of medical education and administration, sat down with us to discuss her experience studying basic science at Vanderbilt and how it played a role in her career. Read MoreJan. 21, 2025
-
Warren Center for Neuroscience Drug Discovery researchers create new compound to potentially treat negative and positive symptoms of schizophrenia
Researchers from the Warren Center for Neuroscience Drug Discovery, in collaboration with Boehringer Ingelheim, developed a compound that can treat both negative and positive symptoms of schizophrenia in rodents. The compound holds promise as an investigational tool and an inspiration for novel schizophrenia therapies. Read MoreJan. 16, 2025
-
Vanderbilt CTTC honors three SOM Basic Sciences faculty as newly inducted Master Innovators
Vanderbilt University has announced this year’s Master Innovators including Carrie Jones, Colleen Niswender, and Alex Waterson. The recognition, presented by the Center for Technology Transfer and Commercialization, honors faculty whose groundbreaking research has been translated into transformative innovations, advancing their fields and making a significant impact on society. Read MoreDec. 5, 2024
-
Drug discovery efforts continue in latest chemical chronicle from the Warren Center for Neuroscience Drug Discovery
Led by Craig W. Lindsley, Vanderbilt drug discovery experts set out to develop a backup drug candidate to improve memory loss in people with Alzheimer’s disease. Read MoreOct. 15, 2024
-
From Lab to Market: Turning ideas into business ventures
Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming cutting-edge research into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read MoreSep. 11, 2024
-
From Lab to Market: Turning ideas into business ventures
Are you sitting on a game-changing idea that could revolutionize your industry? Don't let it gather dust—Vanderbilt University’s expert tech transfer team is here to help you bring it to life. With a proven track record of transforming Vanderbilt researchers’ work into successful business ventures, they possess the knowledge, resources, and connections to transform your innovation from concept to reality. Read MoreSep. 11, 2024
-
Emily Days wins Rosalind Franklin Society Special Award in Science for contributions to the journal ASSAY and Drug Development Technologies
Days’ work to identify highly potent and selective 5-HT2B antagonists was recognized by the Rosalind Franklin Society Read MoreAug. 28, 2024
-
Warren Center for Neuroscience Drug Discovery inaugural open house offers behind-the-scenes drug discovery research
The Warren Center for Neuroscience Drug Discovery opened its doors to the Nashville community to share firsthand the pioneering work it is conducting on Alzheimer’s disease, Parkinson’s disease, addiction, and more. Read MoreJul. 8, 2024
-
New drug candidates targeting blood clots developed through computer-aided drug design
Using computer-aided drug design, the labs of Heidi Hamm, Jens Meiler, and Craig Lindsley generated a novel series of biologically active compounds that can serve as a basis for anti–blood clot preventative drugs. Read MoreJun. 6, 2024